- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06148558
A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+
A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+ in Women With Moderate to Severe Overall Photodamage
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a single center, single-cell, 12-week clinical trial on female subjects (Fitzpatrick Skin Type I-VI, evenly distributed) between 35-60 years of age with moderate to severe overall facial photodamage. All subjects were provided Revision Skincare Gentle Foaming Cleanser and Facial Moisturizer (Goodier Cosmetics) at the Screening visit after eligibility was confirmed. These products were used twice daily as instructed for a minimum 3 days prior to the Baseline visit (washout phase). At Baseline, subjects were given Sunscreen Moisturizer SPF 50+ to replace their Facial Moisturizer morning application. Subjects continued to use the Facial Moisturizer given at Screening in the evening.
Clinical grading assessments, full face images, Corneometer, Ultrasound, and subject self-assessment questionnaires were completed at each study visit (Baseline, Week 4, 8, and 12). Full face images were also completed post-application at Baseline.
A total of 34 subjects completed the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Newtown Square, Pennsylvania, United States, 19073
- Skin Study Center, KGL LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women between the ages of 35 and 60 years
- Women with Fitzpatrick skin type I-VI
- Subjects must have moderate to severe overall facial photodamage
- Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation.
- Subjects must be willing to provide verbal understanding and written informed consent.
Exclusion Criteria:
- Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients in the study product(s).
- Subjects who are currently under a physician's care for a medical problem that, in the opinion of the Investigator or his designee, could affect the subject's treatment response.
- Subjects who are nursing, pregnant, or planning a pregnancy during this study
- Subjects who have a health condition and/or pre-existing or dormant dermatologic disease on the face
- Subjects who are not willing to avoid daily sun exposure on their face and the use of tanning beds or sunless tanning products during the duration of the study.
- Is currently taking or have taken within the listed time frame prior to the start of the study: Oral isotretinoin (Accutane®) within the last 6 months; Avita®, Differin®, Renova®, Retin-A®, Retin-A Micro®, Soriatane®, or Tazorac® within 3 months; Prescription-strength skin-lightening products within 4 months; Any anti-wrinkle, skin-lightening, or other product or topical or systemic medication known to affect skin aging or dyschromia within 2 weeks; Had a non-ablative laser (Including IPL) or non-ablative fractional laser resurfacing of the face and neck within 6 months
- Has any other condition that, in the opinion of the Investigator or his designee, could interfere with the subject's ability to use the treatment as instructed, alter treatment response, or affect their ability to complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single-Cell
|
A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
A provided facial moisturizer (Goodier) was used 1x daily (PM).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Clinical Efficacy Parameters at weeks 4, 8, and 12 versus Baseline
Time Frame: 12 weeks
|
The primary efficacy endpoint will be Investigator Clinical Grading using a Modified Griffiths' 10-point scale.
The scale ranges from 0 = none (best possible condition) to 9 = severe (worst possible condition).
A decrease in score at post-baseline timepoints compared to baseline indicates an improvement.
The parameters are fine lines (global face), wrinkles (global face), global hyperpigmentation (mottled and discrete), skin roughness (tactile), skin tone evenness (uniformity of skin color), overall photodamage, radiance (perceived glow), and skin firmness (tactile).
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lack of significant increase in Objective Tolerability Parameters at weeks 4, 8, and 12 compared to Baseline
Time Frame: 12 weeks
|
The primary tolerability endpoint will be the Investigator Tolerability Assessment of erythema, edema, and scaling/peeling of the face and neck.
The 4-point scale ranges from 0 = none to 3 = severe.
A decrease in score at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Lack of significant increase in Subjective Tolerability Parameters at weeks 4, 8, and 12 compared to Baseline
Time Frame: 12 weeks
|
The secondary tolerability endpoint will be the Subjective Tolerability Assessment of burning/stinging, itching, and tightness/dryness of the face and neck.
The 4-point scale ranges from 0 = none to 3 = severe.
A decrease in score at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Assessment Questionnaire
Time Frame: 12 weeks
|
The secondary efficacy endpoints will be the Self-Assessment Questionnaire on product efficacy and aesthetics.
The 5-point scale ranges from 1 = completely disagree to 5 = completely agree.
An increase in score at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Improvement in skin density at weeks 4, 8, and 12 compared to Baseline
Time Frame: 12 weeks
|
Ultrasound imaging of the left cheek will be used to measure skin density.
An increase in value at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Improvement in skin thickness at weeks 4, 8, and 12 compared to baseline.
Time Frame: 12 weeks
|
Ultrasound imaging of the left cheek will be used to measure skin thickness.
An increase in value at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Improvement in skin hydration at weeks 4, 8, and 12 compared to Baseline
Time Frame: 12 weeks
|
Corneometer measurements of the left cheek will be used to measure hydration content of the skin.
An increase in value at post-baseline timepoints compared to baseline indicates an improvement.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8674
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photoaging
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruiting
-
University of ManchesterUnknownPhotoagingUnited Kingdom
-
Integrative Skin Science and ResearchSytheon Ltd.Not yet recruitingThe Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged SkinPhotoagingUnited States
-
Northwestern UniversityActive, not recruiting
-
Universitätsklinikum Hamburg-EppendorfNot yet recruiting
-
Integrative Skin Science and ResearchNational Mango BoardNot yet recruiting
-
Bausch Health Americas, Inc.Completed
-
Galderma R&DCompletedPhotoagingUnited States
-
Derming SRLCompleted
-
Revision SkincareKGL, Inc.CompletedWrinkle | PhotoagingUnited States
Clinical Trials on Sunscreen Moisturizer
-
Revision SkincareStephens & Associates, Inc.CompletedSkin Care | Photodamaged SkinUnited States
-
HALEONCompletedSunscreening AgentsUnited States
-
GlaxoSmithKlineCompletedSunscreening AgentsUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedSunscreenUnited States
-
Revision SkincareKGL, Inc.CompletedWrinkle | PhotoagingUnited States
-
Revision SkincareAblon Skin Institute Research CenterCompletedWrinkles | Photoaging | Fine LinesUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)Withdrawn
-
Revision SkincareValidated Claim SupportCompletedWrinkle | Periorbital Edema | Fine Lines | Periorbital HyperpigmentationUnited States
-
Herbarium Laboratorio Botanico LtdaNot yet recruiting
-
Libbs Farmacêutica LTDACompleted